Questionnaire results. by Alexander Neugebauer (2425123)

Parameters for the simulated annealing algorithm. by Billy Tchounke (16965084)

ELMO1 downmodulation in human CB CD34+ cells does not alter growth, colony formation or differentiation, but significantly decreases stem cell frequency. by Marta E. Capala (652765)

Cobalt-Catalyzed C(sp²)–C(sp³) Suzuki–Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands by L. Reginald Mills (4356334)

“…The protocol enabled efficient C–C bond formation with a host of nucleophiles and electrophiles (36 examples, 34–95%) with precatalyst loadings of 5 mol %. …”

Cobalt-Catalyzed C(sp²)–C(sp³) Suzuki–Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands by L. Reginald Mills (4356334)

“…The protocol enabled efficient C–C bond formation with a host of nucleophiles and electrophiles (36 examples, 34–95%) with precatalyst loadings of 5 mol %. …”

Cobalt-Catalyzed C(sp²)–C(sp³) Suzuki–Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands by L. Reginald Mills (4356334)

“…The protocol enabled efficient C–C bond formation with a host of nucleophiles and electrophiles (36 examples, 34–95%) with precatalyst loadings of 5 mol %. …”

Cobalt-Catalyzed C(sp²)–C(sp³) Suzuki–Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands by L. Reginald Mills (4356334)

“…The protocol enabled efficient C–C bond formation with a host of nucleophiles and electrophiles (36 examples, 34–95%) with precatalyst loadings of 5 mol %. …”

Cobalt-Catalyzed C(sp²)–C(sp³) Suzuki–Miyaura Cross-Coupling Enabled by Well-Defined Precatalysts with L,X-Type Ligands by L. Reginald Mills (4356334)

“…The protocol enabled efficient C–C bond formation with a host of nucleophiles and electrophiles (36 examples, 34–95%) with precatalyst loadings of 5 mol %. …”

Genetic parameters in the initial Deli, La Mé and hybrids populations obtained by simulation. by Billy Tchounke (16965084)

Quantification of blood flow at the angiogenic front. by Fatemeh Mirzapour-Shafiyi (10981427)

Integrin αVβ5 antibody inhibits the uptake of ROS by piPSC-RPE cells. by Jie Gong (339362)

“…Addition of an inhibitory anti-integrin αVβ5 antibody significantly decreased phagocytosis by approximately 50% in piPSC-RPE cells. …”

Table_1_Decreased water temperature enhance Piscine orthoreovirus genotype 3 replication and severe heart pathology in experimentally infected rainbow trout.XLSX by Juliane Sørensen (14596838)

Effects of covid-19 lockdown on physical activity, sedentary behavior, and satisfaction with life in Qatar: A preliminary study by Hermassi, Souhail

Get full text
Get full text

Simultaneously inhibition <i>Nlu-miR-34</i> and <i>NlInR2</i> in SW strain induced the decrease of SW BPHs. by Xinhai Ye (6857771)

“…<p>(A) Antagomir-34 (with two different quantities) and ds<i>NlInR2</i> (0.84 ng) were injected into the third instar SW strain nymphs, showed that injection of antagomir-34 decreased the ratio of SW type BPH (Chi-square test, 40ng: χ² = 5.8, df = 1, <i>p</i> = 0.003; 60ng: χ² = 7.9, df = 1, <i>p</i> = 0.042). …”

Fig 6 - by Billy Tchounke (16965084)

Annual genetic progress for FFB (in percentage of hybrids performance at generation 0) according to method of selection and mating and breeding scheme (RRS with 120 candidates, RRG... by Billy Tchounke (16965084)

Inbreeding computed with the SNPs in the La Mé population after four breeding cycles according to method of selection and mating and breeding scheme (RRS with 120 candidates, RRGS... by Billy Tchounke (16965084)

Gallium efficiently inhibits AzEvC10 siderophore production and proliferation during macrophage infection. by Mylene Vaillancourt (7409486)

IL-4Rα deficiency in CD4⁺ T cells results in decreased non-specific Th2 responses in female mice. by Karen J. Bryson (233681)

Table_5_SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.xlsx by Monica Franzese (8983097)

“…The cohorts were monitored from the 12th day after the first vaccine dose up to 1 month after the third vaccine dose for a total of eight time points and about 1 year of surveillance (T1 = 12 days after the first dose; T2 = 10 days after the second dose; T3 = 1 month after the second dose; T4 = 3 months after the second dose; T5 = 4 months after the second dose; T6 = 5 months after the second dose; T7 = 7 months after the second dose; T8 = 1 month after the third dose for Group 1; T8* = 9 months after the second dose for Group 2; T9 = 1 month after the third dose for Group 2). …”